Article Information
History
- January 18, 2021.
Article Versions
- Version 1 (April 26, 2020 - 15:42).
- Version 2 (November 6, 2020 - 14:55).
- Version 3 (January 10, 2021 - 09:24).
- Version 4 (January 10, 2021 - 11:06).
- You are viewing Version 5, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Dr Fasihul Khan1,*,
- Dr Iain Stewart1,
- Dr Laura Fabbri1,
- Samuel Moss1,
- Professor Karen A. Robinson2,
- Professor Alan Smyth3 and
- Professor Gisli Jenkins1
- 1Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK
- 2John Hopkins University
- 3Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Nottingham, UK
- ↵*Correspondence to: Dr Fasihul Khan fasihul.khan{at}nottingham.ac.uk
Posted January 18, 2021.
A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19
